Since we have previously tested galunisertib, a potent TGF-βR1 inhibitor, and found it to be highly efficacious in SW480 VMT, we also treated pVMT with galunisertib to determine if TGF-βR1 warrants further investigation as a novel target in CRC. This evidence concerns the gene TGFBR1 and colorectal carcinoma.